Cynapsus Therapeutics Inc Stock

Equities

Delayed Toronto S.E. Other stock markets			5-day change	1st Jan Change
- ^CAD	-.--%		+0.21%	-.--%

Mar. 11	Mkango and CoTec Brief: Mkango Subsidiary, Maginito, And CoTec Appointed Lead Engineers BBA And Pegasus To Complete Feasibility Study for HyProMag USA	MT
Jan. 29	CoTec Holdings Outlines Key Targets For 2024	MT

Duration

Period

Style

Mkango and CoTec Brief: Mkango Subsidiary, Maginito, And CoTec Appointed Lead Engineers BBA And Pegasus To Complete Feasibility Study for HyProMag USA	Mar. 11	MT
CoTec Holdings Outlines Key Targets For 2024	Jan. 29	MT
Mkango Surges Near 12% As Forms HyProMag Joint Venture In US With CoTec	Jan. 03	MT
Mkango Surges 11% As Says To Commence Feasibility Study For Proposed US Operation With CoTec	23-10-10	MT
Mkango, CoTec To Commence Feasibility Study For Proposed US Operation	23-10-10	MT
CoTec Completed Conversion of 2 Million Pounds Mkango Loan Note to Double Equity Position in Maginito to 20.6%	23-10-02	MT
Mkango Down Near 3% As Agrees To Form US Joint Venture With CoTec Holdings	23-09-14	MT
CoTec Holdings, Mkango To Form US Joint Venture	23-09-14	MT
Kings Chapel Increases Stake In CoTec Holdings	23-06-30	MT
CoTec Holdings Up 11% as it Raises Its Stake in MagIron LLC as Its Holding is now Worth More Than its Stock-Market Value	23-06-19	MT
Mako Mining Commences Work at Las Conchitas; Processing of Material Expected in July	23-06-19	MT
Mkango Up 9% In Mid-Afternoon UK Trade As Maginito Moves To Buy Pioneering Rare Earth Magnet Recycler HyProMag	23-05-16	MT
CoTec Holdings Corp. Increases Interest in MagIron; CTH Lost Near 11% on Friday	23-05-01	MT
CoTec Holdings Jumps 12% As Reports Maiden Annual Profit For 2022	23-04-21	MT
CoTec Holdings Reports Maiden Annual Profit For 2022	23-04-21	MT

Cynapsus Therapeutics : Sunovion Pharmaceuticals to Acquire Cynapsus Therapeutics	16-08-31	PU
Cynapsus Therapeutics : Receives FDA Fast Track Designation for APL-130277 for the Treatment of OFF Episodes in Patients with Parkinson's Disease	16-08-29	GL
Cynapsus Therapeutics : Announces Positive Opinion from Data and Safety Monitoring Board on Phase 3 Parkinson's Disease Clinical Study Allowing for At-Home Titration	16-08-15	GL
Cynapsus Therapeutics : Announces Publication in the Journal Movement Disorders of Data for the Treatment of OFF Episodes in Patients with Parkinson's Disease	16-08-12	GL
Cynapsus Therapeutics : Reports Second Quarter 2016 Financial Results and Recent Developments	16-08-10	GL

Sector

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	-3.10%	102B
REGENERON PHARMACEUTICALS, INC.	+2.11%	96.07B
ARGENX SE	-1.80%	21.66B
BIONTECH SE	-17.75%	20.77B
GENMAB A/S	-6.91%	18.53B
WUXI APPTEC CO., LTD.	-42.00%	16.91B
BEIGENE, LTD.	-28.19%	13.79B
NEUROCRINE BIOSCIENCES, INC.	+0.18%	13.33B
SAREPTA THERAPEUTICS, INC.	+19.90%	10.94B